Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Eddingpharm Gains China Rights for Cancer Drug from Syndax

publication date: Sep 4, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eddingpharm has in-licensed China rights to a clinical-stage cancer treatment from Syndax Pharma of Massachusetts. Entinostat is an oral epigenetic drug that was designed to reverse resistance to targeted oncology therapies. Eddingpharm will develop the drug in China, a process that includes participating in Syndax’s global Phase III trials of the drug. It will also have manufacturing rights to entinostat. Syndax will receive milestone and royalty payments from Eddingpharm for entinostat, though specific amounts were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors